Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19567523 | 1.00 | OPRM1 (0.51) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL24093352 | 1.00 | OPRM1 (0.51) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL23514499 | 0.93 | MEN1 (0.55) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL19568084 | 0.93 | MEN1 (0.55) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL23514752 | 0.87 | POLB (0.50) | OPRM1OPRL1ACHEBACE1BCHE | |
| SCHEMBL20781847 | 0.87 | JAK2 (0.42) | OPRM1OPRL1ACHEBACE1BCHE | |
| SCHEMBL23514509 | 0.87 | JAK2 (0.42) | OPRM1OPRL1JAK2JAK1 | |
| SCHEMBL19568085 | 0.87 | JAK2 (0.42) | OPRM1OPRL1JAK2JAK1 | |
| SCHEMBL19568076 | 0.86 | MAOA (0.45) | OPRM1OPRL1JAK2JAK1 | |
| SCHEMBL19567881 | 0.86 | MAOA (0.45) | OPRM1OPRL1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | OPRM1 2365/4885OPRL1 2515/4885GRIN2B 1057/4885 |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | OPRM1 2365/4885OPRL1 2515/4885GRIN2B 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.